Abstract
Objective: The aim was to formulate practice guidelines for the diagnosis and management of congenital hypothyroidism (CH). Evidence: A systematic literature search was conducted to identify key articles relating to the screening, diagnosis, and management of CH. The evidence-based guidelines were developed with the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system, describing both the strength of recommendations and the quality of evidence. In the absence of sufficient evidence, conclusions were based on expert opinion. Consensus Process: Thirty-two participants drawn from the European Society for Paediatric Endocrinology and five other major scientific societies in the field of pediatric endocrinology were allocated to working groups with assigned topics and specific questions. Each group searched the literature, evaluated the evidence, and developed a draft document. These papers were debated and finalized by each group before presentation to the full assembly for further discussion and agreement. Recommendations: The recommendations include: worldwide neonatal screening, approaches to assess the cause (including genotyping) and the severity of the disorder, the immediate initiation of appropriate L-T4 supplementation and frequent monitoring to ensure dose adjustments to keep thyroid hormone levels in the target ranges, a trial of treatment in patients suspected of transient CH, regular assessments of developmental and neurosensory functions, consulting health professionals as appropriate, and education about CH. The harmonization of diagnosis, management, and routine health surveillance would not only optimize patient outcomes, but should also facilitate epidemiological studies of the disorder. Individuals with CH require monitoring throughout their lives, particularly during early childhood and pregnancy.
References
1.
Grosse SD, Van Vliet G: Prevention of intellectual disability through screening for congenital hypothyroidism: how much and at what level? Arch Dis Child 2011;96:374-379.
2.
Pearce MS, McNally RJ, Day J, Korada SM, Turner S, Cheetham TD: Space-time clustering of elevated thyroid stimulating hormone levels. Eur J Epidemiol 2011;26:405-411.
3.
Deladoëy J, Ruel J, Giguère Y, Van Vliet G: Is the incidence of congenital hypothyroidism really increasing? A 20-year retrospective population-based study in Québec. J Clin Endocrinol Metab 2011;96:2422-2429.
4.
Olivieri A, Corbetta C, Weber G, et al: Congenital hypothyroidism due to defects of thyroid development and mild increase of TSH at screening: data from the Italian National Registry of Infants with Congenital Hypothyroidism. J Clin Endocrinol Metab 2013;98:1403-1408.
5.
Calaciura F, Motta RM, Miscio G, et al: Subclinical hypothyroidism in early childhood: a frequent outcome of transient neonatal hyperthyrotropinemia. J Clin Endocrinol Metab 2002;87:3209-3214.
6.
Rapaport R: Congenital hypothyroidism: an evolving common clinical conundrum. J Clin Endocrinol Metab 2010;95:4223-4225.
7.
Swiglo BA, Murad MH, Schünemann HJ, et al: A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 2008;93:666-673.
8.
Rose SR, Brown RS, Foley T, et al: Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 2006;117:2290-2303.
9.
LaFranchi SH: Approach to the diagnosis and treatment of neonatal hypothyroidism. J Clin Endocrinol Metab 2011;96:2959-2967.
10.
Zoeller RT, Rovet J: Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings. J Neuroendocrinol 2004;16:809-818.
11.
Geelhoed EA, Lewis B, Hounsome D, O'leary P: Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism. J Paediatr Child Health 2005;41:575-579.
12.
Rastogi MV, LaFranchi SH: Congenital hypothyroidism. Orphanet J Rare Dis 2010;5:17.
13.
Grüters A, Krude H: Detection and treatment of congenital hypothyroidism. Nat Rev Endocrinol 2012;8:104-113.
14.
Chen ZP, Hetzel BS: Cretinism revisited. Best Pract Res Clin Endocrinol Metab 2010;24:39-50.
15.
Gilbert ME, Rovet J, Chen Z, Koibuchi N: Developmental thyroid hormone disruption: prevalence, environmental contaminants and neurodevelopmental consequences. Neurotoxicology 2012;33:842-852.
16.
Zimmermann MB, Aeberli I, Torresani T, Bürgi H: Increasing the iodine concentration in the Swiss iodized salt program markedly improved iodine status in pregnant women and children: a 5-y prospective national study. Am J Clin Nutr 2005;82:388-392.
17.
LaFranchi SH: Newborn screening strategies for congenital hypothyroidism: an update. J Inherit Metab Dis 2010;33:S225-S233.
18.
Klein AH, Agustin AV, Foley TP Jr: Successful laboratory screening for congenital hypothyroidism. Lancet 1974;2:77-79.
19.
Corbetta C, Weber G, Cortinovis F, et al: A 7-year experience with low blood TSH cutoff levels for neonatal screening reveals an unsuspected frequency of congenital hypothyroidism (CH). Clin Endocrinol (Oxf) 2009;71:739-745.
20.
Mengreli C, Kanaka-Gantenbein C, Girginoudis P, et al: Screening for congenital hypothyroidism: the significance of threshold limit in false-negative results. J Clin Endocrinol Metab 2010;95:4283-4290.
21.
van Tijn DA, de Vijlder JJ, Verbeeten B Jr, Verkerk PH, Vulsma T: Neonatal detection of congenital hypothyroidism of central origin. J Clin Endocrinol Metab 2005;90:3350-3359.
22.
Fisher D: Next generation newborn screening for congenital hypothyroidism? J Clin Endocrinol Metab 2005;90:3797-3799.
23.
Lanting CI, van Tijn DA, Loeber JG, Vulsma T, de Vijlder JJ, Verkerk PH: Clinical effectiveness and cost-effectiveness of the use of the thyroxine/thyroxine-binding globulin ratio to detect congenital hypothyroidism of thyroidal and central origin in a neonatal screening program. Pediatrics 2005;116:168-173.
24.
Nebesio TD, McKenna MP, Nabhan ZM, Eugster EA: Newborn screening results in children with central hypothyroidism. J Pediatr 2010;156:990-993.
25.
Adams LM, Emery JR, Clark SJ, Carlton EI, Nelson JC: Reference ranges for newer thyroid function tests in premature infants. J Pediatr 1995;126:122-127.
26.
Mitchell ML, Walraven C, Rojas DA, McIntosh KF, Hermos RJ: Screening very-low-birthweight infants for congenital hypothyroidism. Lancet 1994;343:60-61.
27.
Woo HC, Lizarda A, Tucker R, et al: Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants: incidence and growth and developmental outcomes. J Pediatr 2011;158:538-542.
28.
LaFranchi SH, Hanna CE, Krainz PL, Skeels MR, Miyahira RS, Sesser DE: Screening for congenital hypothyroidism with specimen collection at two time periods: results of the Northwest Regional Screening Program. Pediatrics 1985;76:734-740.
29.
Rapaport R: Evaluation of thyroid status of infants in intensive care settings: recommended an extension of newborn screening. J Pediatr 2003;143:556-558.
30.
Re RN, Kourides IA, Ridgway EC, Weintraub BD, Maloof F: The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. J Clin Endocrinol Metab 1976;43:338-346.
31.
Filippi L, Pezzati M, Poggi C, Rossi S, Cecchi A, Santoro C: Dopamine versus dobutamine in very low birthweight infants: endocrine effects. Arch Dis Child Fetal Neonatal Ed 2007;92:F367-F371.
32.
Fisher DA: Thyroid system immaturities in very low birth weight premature infants. Semin Perinatol 2008;32:387-397.
33.
Olivieri A, Medda E, De Angelis S, et al: High risk of congenital hypothyroidism in multiple pregnancies. J Clin Endocrinol Metab 2007;92:3141-3147.
34.
Williams FL, Ogston SA, van Toor H, Visser TJ, Hume R: Serum thyroid hormones in preterm infants: associations with postnatal illnesses and drug usage. J Clin Endocrinol Metab 2005;90:5954-5963.
35.
Golombek SG: Nonthyroidal illness syndrome and euthyroid sick syndrome in intensive care patients. Semin Perinatol 2008;32:413-418.
36.
Goldsmit GS, Valdes M, Herzovich V, et al: Evaluation and clinical application of changes in thyroid hormone and TSH levels in critically ill full-term newborns. J Perinat Med 2011;39:59-64.
37.
Bongers-Schokking JJ, Schopman W: Thyroid function in healthy normal, low birthweight and preterm infants. Eur J Pediatr 1984;143:117-122.
38.
LaFranchi S: Thyroid function in the preterm infant. Thyroid 1999;9:71-78.
39.
Mäenpää J: Congenital hypothyroidism. Aetiological and clinical aspects. Arch Dis Child 1972;47:914-923.
40.
Spencer CA, LoPresti JS, Patel A, et al: Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 1990;70:453-460.
41.
Eugster EA, LeMay D, Zerin JM, Pescovitz OH: Definitive diagnosis in children with congenital hypothyroidism. J Pediatr 2004;144:643-647.
42.
Krude H, Blankenstein O: Treating patients not numbers: the benefit and burden of lowering TSH newborn screening cut-offs. Arch Dis Child 2011;96:121-122.
43.
Freire C, Ramos R, Amaya E, et al: Newborn TSH concentration and its association with cognitive development in healthy boys. Eur J Endocrinol 2010;163:901-909.
44.
Toublanc JE: Guidelines for neonatal screening programs for congenital hypothyroidism. Working Group for Neonatal Screening in Paediatric Endocrinology of the European Society for Paediatric Endocrinology. Acta Paediatr Suppl 1999;88:13-14.
45.
Jones JH, Donaldson MD: Audit of initial management of congenital hypothyroidism in the United Kingdom - comparison of UK practice with European and UK guidelines. J Pediatr Endocrinol Metab 2009;22:1017-1025.
46.
Léger J, Ecosse E, Roussey M, Lanoë JL, Larroque B: Subtle health impairment and socioeducational attainment in young adult patients with congenital hypothyroidism diagnosed by neonatal screening: a longitudinal population-based cohort study. J Clin Endocrinol Metab 2011;96:1771-1782.
47.
Glorieux J, Desjardins M, Letarte J, Morissette J, Dussault JH: Useful parameters to predict the eventual mental outcome of hypothyroid children. Pediatr Res 1988;24:6-8.
48.
Wasniewska M, De Luca F, Cassio A, et al: In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first year of life irrespective of other variables related to treatment. Eur J Endocrinol 2003;149:1-6.
49.
Tillotson SL, Fuggle PW, Smith I, Ades AE, Grant DB: Relation between biochemical severity and intelligence in early treated congenital hypothyroidism: a threshold effect. BMJ 1994;309:440-445.
50.
Mutlu M, Karagüzel G, Alıyaziciolu Y, Eyüpolu I, Okten A, Aslan Y: Reference intervals for thyrotropin and thyroid hormones and ultrasonographic thyroid volume during the neonatal period. J Matern Fetal Neonatal Med 2012;25:120-124.
51.
Schoen EJ, Clapp W, To TT, Fireman BH: The key role of newborn thyroid scintigraphy with isotopic iodide [123I] in defining and managing congenital hypothyroidism. Pediatrics 2004;114:e683-e688.
52.
Clerc J, Monpeyssen H, Chevalier A, et al: Scintigraphic imaging of paediatric thyroid dysfunction. Horm Res 2008;70:1-13.
53.
Szinnai G, Kosugi S, Derrien C, et al: Extending the clinical heterogeneity of iodide transport defect (ITD): a novel mutation R124H of the sodium/iodide symporter gene and review of genotype-phenotype correlations in ITD. J Clin Endocrinol Metab 2006;91:1199-1204.
54.
Bubuteishvili L, Garel C, Czernichow P, Léger J: Thyroid abnormalities by ultrasonography in neonates with congenital hypothyroidism. J Pediatr 2003;143:759-764.
55.
Karakoc-Aydiner E, Turan S, Akpinar I, et al: Pitfalls in the diagnosis of thyroid dysgenesis by thyroid ultrasonography and scintigraphy. Eur J Endocrinol 2012;166:43-48.
56.
Marinovic D, Garel C, Czernichow P, Léger J: Ultrasonographic assessment of the ectopic thyroid tissue in children with congenital hypothyroidism. Pediatr Radiol 2004;34:109-113.
57.
Ohnishi H, Sato H, Noda H, Inomata H, Sasaki N: Color Doppler ultrasonography: diagnosis of ectopic thyroid gland in patients with congenital hypothyroidism caused by thyroid dysgenesis. J Clin Endocrinol Metab 2003;88:5145-5149.
58.
Jones JH, Attaie M, Maroo S, Neumann D, Perry R, Donaldson MD: Heterogeneous tissue in the thyroid fossa on ultrasound in infants with proven thyroid ectopia on isotope scan - a diagnostic trap. Pediatr Radiol 2010;40:725-731.
59.
Marinovic D, Garel C, Czernichow P, Léger J: Additional phenotypic abnormalities with presence of cysts within the empty thyroid area in patients with congenital hypothyroidism with thyroid dysgenesis. J Clin Endocrinol Metab 2003;88:1212-1216.
60.
Gaudino R, Garel C, Czernichow P, Léger J: Proportion of various types of thyroid disorders among newborns with congenital hypothyroidism and normally located gland: a regional cohort study. Clin Endocrinol (Oxf) 2005;62:444-448.
61.
Castanet M, Polak M, Bonaïti-Pellié C, Lyonnet S, Czernichow P, Léger J: Nineteen years of national screening for congenital hypothyroidism: familial cases with thyroid dysgenesis suggest the involvement of genetic factors. J Clin Endocrinol Metab 2001;86:2009-2014.
62.
Olivieri A, Stazi MA, Mastroiacovo P, et al: A population-based study on the frequency of additional congenital malformations in infants with congenital hypothyroidism: data from the Italian Registry for Congenital Hypothyroidism (1991-1998). J Clin Endocrinol Metab 2002;87:557-562.
63.
Roberts HE, Moore CA, Fernhoff PM, Brown AL, Khoury MJ: Population study of congenital hypothyroidism and associated birth defects, Atlanta, 1979-1992. Am J Med Genet 1997;71:29-32.
64.
Azar-Kolakez A, Ecosse E, Dos Santos S, Léger J: All-cause and disease-specific mortality and morbidity in patients with congenital hypothyroidism treated since the neonatal period: a national population-based study. J Clin Endocrinol Metab 2013;98:785-793.
65.
Kumar J, Gordillo R, Kaskel FJ, Druschel CM, Woroniecki RP: Increased prevalence of renal and urinary tract anomalies in children with congenital hypothyroidism. J Pediatr 2009;154:263-266.
66.
Oakley GA, Muir T, Ray M, Girdwood RW, Kennedy R, Donaldson MD: Increased incidence of congenital malformations in children with transient thyroid-stimulating hormone elevation on neonatal screening. J Pediatr 1998;132:726-730.
67.
van Trotsenburg AS, Vulsma T, van Santen HM, Cheung W, de Vijlder JJ: Lower neonatal screening thyroxine concentrations in Down syndrome newborns. J Clin Endocrinol Metab 2003;88:1512-1515.
68.
Cassio A, Cacciari E, Cicognani A, et al: Treatment for congenital hypothyroidism: thyroxine alone or thyroxine plus triiodothyronine? Pediatrics 2003;111:1055-1060.
69.
Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L: Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2006;91:2592-2599.
70.
von Heppe JH, Krude H, L'Allemand D, Schnabel D, Grüters A: The use of L-T4 as liquid solution improves the practicability and individualized dosage in newborns and infants with congenital hypothyroidism. J Pediatr Endocrinol Metab 2004;17:967-974.
71.
DiStefano JJ 3rd, Mak PH: On model and data requirements for determining the bioavailability of oral therapeutic agents: application to gut absorption of thyroid hormones. Am J Physiol 1979;236:R137-R141.
72.
Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH: Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987;316:764-770.
73.
Cassio A, Monti S, Rizzello A, et al: Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. J Pediatr 2013;162:1264-1269.
74.
Carswell JM, Gordon JH, Popovsky E, Hale A, Brown RS: Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism. J Clin Endocrinol Metab 2013;98:610-617.
75.
Tau C, Garabedian M, Farriaux JP, Czernichow P, Pomarede R, Balsan S: Hypercalcemia in infants with congenital hypothyroidism and its relation to vitamin D and thyroid hormones. J Pediatr 1986;109:808-814.
76.
Leger J, Tau C, Garabedian M, Farriaux JP, Czernichow P: Prophylaxis of vitamin D deficiency in hypothyroidism in the newborn infant (in French). Arch Fr Pediatr 1989;46:567-571.
77.
Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JG, Berghout A: Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med 2010;170:1996-2003.
78.
Dimitropoulos A, Molinari L, Etter K, et al: Children with congenital hypothyroidism: long-term intellectual outcome after early high-dose treatment. Pediatr Res 2009;65:242-248.
79.
Boileau P, Bain P, Rives S, Toublanc JE: Earlier onset of treatment or increment in LT4 dose in screened congenital hypothyroidism: which is the more important factor for IQ at 7 years? Horm Res 2004;61:228-233.
80.
Grüters A, Liesenkötter KP, Zapico M, et al: Results of the screening program for congenital hypothyroidism in Berlin (1978-1995). Exp Clin Endocrinol Diabetes 1997;105(suppl 4):28-31.
81.
Rovet JF, Ehrlich RM: Long-term effects of L-thyroxine therapy for congenital hypothyroidism. J Pediatr 1995;126:380-386.
82.
Kempers MJ, van der Sluijs Veer L, Nijhuis-van der Sanden RW, et al: Neonatal screening for congenital hypothyroidism in The Netherlands: cognitive and motor outcome at 10 years of age. J Clin Endocrinol Metab 2007;92:919-924.
83.
Glorieux J, Dussault J, Van Vliet G: Intellectual development at age 12 years of children with congenital hypothyroidism diagnosed by neonatal screening. J Pediatr 1992;121:581-584.
84.
Simons WF, Fuggle PW, Grant DB, Smith I: Intellectual development at 10 years in early treated congenital hypothyroidism. Arch Dis Child 1994;71:232-234.
85.
Rovet J, Ehrlich R, Sorbara D: Intellectual outcome in children with fetal hypothyroidism. J Pediatr 1987;110:700-704.
86.
Kempers MJ, van der Sluijs Veer L, Nijhuis-van der Sanden MW, et al: Intellectual and motor development of young adults with congenital hypothyroidism diagnosed by neonatal screening. J Clin Endocrinol Metab 2006;91:418-424.
87.
Huo K, Zhang Z, Zhao D, et al: Risk factors for neurodevelopmental deficits in congenital hypothyroidism after early substitution treatment. Endocr J 2011;58:355-361.
88.
Salerno M, Militerni R, Bravaccio C, et al: Effect of different starting doses of levothyroxine on growth and intellectual outcome at four years of age in congenital hypothyroidism. Thyroid 2002;12:45-52.
89.
Simoneau-Roy J, Marti S, Deal C, Huot C, Robaey P, Van Vliet G: Cognition and behavior at school entry in children with congenital hypothyroidism treated early with high-dose levothyroxine. J Pediatr 2004;144:747-752.
90.
Selva KA, Harper A, Downs A, Blasco PA, Lafranchi SH: Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH. J Pediatr 2005;147:775-780.
91.
Bongers-Schokking JJ, de Muinck Keizer-Schrama SM: Influence of timing and dose of thyroid hormone replacement on mental, psychomotor, and behavioral development in children with congenital hypothyroidism. J Pediatr 2005;147:768-774.
92.
Selva KA, Mandel SH, Rien L, et al: Initial treatment dose of L-thyroxine in congenital hypothyroidism. J Pediatr 2002;141:786-792.
93.
Heyerdahl S, Oerbeck B: Congenital hypothyroidism: developmental outcome in relation to levothyroxine treatment variables. Thyroid 2003;13:1029-1038.
94.
Vogiatzi MG, Kirkland JL: Frequency and necessity of thyroid function tests in neonates and infants with congenital hypothyroidism. Pediatrics 1997;100:E6.
95.
Mathai S, Cutfield WS, Gunn AJ, et al: A novel therapeutic paradigm to treat congenital hypothyroidism. Clin Endocrinol (Oxf) 2008;69:142-147.
96.
Balhara B, Misra M, Levitsky LL: Clinical monitoring guidelines for congenital hypothyroidism: laboratory outcome data in the first year of life. J Pediatr 2011;158:532-537.
97.
Penfold JL, Simpson DA: Premature craniosynostosis - a complication of thyroid replacement therapy. J Pediatr 1975;86:360-363.
98.
Salerno M, Oliviero U, Lettiero T, et al: Long-term cardiovascular effects of levothyroxine therapy in young adults with congenital hypothyroidism. J Clin Endocrinol Metab 2008;93:2486-2491.
99.
Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP: Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010;95:186-193.
100.
Raghavan S, DiMartino-Nardi J, Saenger P, Linder B: Pseudotumor cerebri in an infant after L-thyroxine therapy for transient neonatal hypothyroidism. J Pediatr 1997;130:478-480.
101.
Aydin A, Cemeroglu AP, Baklan B: Thyroxine-induced hypermotor seizure. Seizure 2004;13:61-65.
102.
Tenenbaum-Rakover Y, Grasberger H, Mamanasiri S, et al: Loss-of-function mutations in the thyrotropin receptor gene as a major determinant of hyperthyrotropinemia in a consanguineous community. J Clin Endocrinol Metab 2009;94:1706-1712.
103.
Rabbiosi S, Vigone MC, Cortinovis F, et al: Congenital hypothyroidism with eutopic thyroid gland: analysis of clinical and biochemical features at diagnosis and after re-evaluation. J Clin Endocrinol Metab 2013;98:1395-1402.
104.
Moreno JC, Bikker H, Kempers MJ, et al: Inactivating mutations in the gene for thyroid oxidase 2 (THOX2) and congenital hypothyroidism. N Engl J Med 2002;347:95-102.
105.
Moreno JC, Visser TJ: New phenotypes in thyroid dyshormonogenesis: hypothyroidism due to DUOX2 mutations. Endocr Dev 2007;10:99-117.
106.
Parazzini C, Baldoli C, Scotti G, Triulzi F: Terminal zones of myelination: MR evaluation of children aged 20-40 months. AJNR Am J Neuroradiol 2002;23:1669-1673.
107.
Abalovich M, Amino N, Barbour LA, et al: Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007;92:S1-S47.
108.
Stagnaro-Green A, Abalovich M, Alexander E, et al: Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011;21:1081-1125.
109.
De Groot L, Abalovich M, Alexander EK, et al: Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2543-2565.
110.
Rovet JF, Ehrlich R: Psychoeducational outcome in children with early-treated congenital hypothyroidism. Pediatrics 2000;105:515-522.
111.
Rovet JF: Children with congenital hypothyroidism and their siblings: do they really differ? Pediatrics 2005;115:e52-e57.
112.
Léger J, Larroque B, Norton J: Influence of severity of congenital hypothyroidism and adequacy of treatment on school achievement in young adolescents: a population-based cohort study. Acta Paediatr 2001;90:1249-1256.
113.
Bisacchi N, Bal MO, Nardi L, et al: Psychological and behavioural aspects in children and adolescents with congenital hypothyroidism diagnosed by neonatal screening: comparison between parents' and children's perceptions. Eur J Endocrinol 2011;164:269-276.
114.
Rovet J, Alvarez M: Thyroid hormone and attention in school-age children with congenital hypothyroidism. J Child Psychol Psychiatry 1996;37:579-585.
115.
Alvarez M, Iglesias Fernández C, Rodríguez Sánchez A, Dulín Lñiguez E, Rodríguez Arnao MD: Episodes of overtreatment during the first six months in children with congenital hypothyroidism and their relationships with sustained attention and inhibitory control at school age. Horm Res Paediatr 2010;74:114-120.
116.
Oerbeck B, Reinvang I, Sundet K, Heyerdahl S: Young adults with severe congenital hypothyroidism: cognitive event related potentials (ERPs) and the significance of an early start of thyroxine treatment. Scand J Psychol 2007;48:61-67.
117.
Wheeler SM, Willoughby KA, McAndrews MP, Rovet JF: Hippocampal size and memory functioning in children and adolescents with congenital hypothyroidism. J Clin Endocrinol Metab 2011;96:E1427-E1434.
118.
Hauri-Hohl A, Dusoczky N, Dimitropoulos A, et al: Impaired neuromotor outcome in school-age children with congenital hypothyroidism receiving early high-dose substitution treatment. Pediatr Res 2011;70:614-618.
119.
Bess FH, Dodd-Murphy J, Parker RA: Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 1998;19:339-354.
120.
François M, Bonfils P, Leger J, Czernichow P, Narcy P: Role of congenital hypothyroidism in hearing loss in children. J Pediatr 1994;124:444-446.
121.
Rovet J, Walker W, Bliss B, Buchanan L, Ehrlich R: Long-term sequelae of hearing impairment in congenital hypothyroidism. J Pediatr 1996;128:776-783.
122.
van der Sluijs Veer L, Kempers MJ, Last BF, Vulsma T, Grootenhuis MA: Quality of life, developmental milestones, and self-esteem of young adults with congenital hypothyroidism diagnosed by neonatal screening. J Clin Endocrinol Metab 2008;93:2654-2661.
123.
Sato H, Nakamura N, Harada S, Kakee N, Sasaki N: Quality of life of young adults with congenital hypothyroidism. Pediatr Int 2009;51:126-131.
124.
Kemper AR, Ouyang L, Grosse SD: Discontinuation of thyroid hormone treatment among children in the United States with congenital hypothyroidism: findings from health insurance claims data. BMC Pediatr 2010;10:9.
125.
Delvecchio M, Salerno M, Acquafredda A, et al: Factors predicting final height in early treated congenital hypothyroid patients. Clin Endocrinol (Oxf) 2006;65:693-697.
126.
Livadas S, Magiakou MA, Mengreli C, et al: Obesity and attenuated adiposity rebound in children with congenital hypothyroidism. Normalization of BMI values in adolescents. Horm Metab Res 2007;39:524-528.
127.
Bucher H, Prader A, Illig R: Head circumference, height, bone age and weight in 103 children with congenital hypothyroidism before and during thyroid hormone replacement. Helv Paediatr Acta 1985;40:305-316.
128.
Salerno M, Micillo M, Di Maio S, et al: Longitudinal growth, sexual maturation and final height in patients with congenital hypothyroidism detected by neonatal screening. Eur J Endocrinol 2001;145:377-383.
129.
Hassani Y, Larroque B, Dos Santos S, Ecosse E, Bouyer J, Léger J: Fecundity in young adults treated early for congenital hypothyroidism is related to the initial severity of the disease: a longitudinal population-based cohort study. J Clin Endocrinol Metab 2012;97:1897-1904.
130.
Leger J, Ruiz JC, Guibourdenche J, Kindermans C, Garabedian M, Czernichow P: Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L-thyroxine therapy. Acta Paediatr 1997;86:704-710.
131.
Salerno M, Lettiero T, Esposito-del Puente A, et al: Effect of long-term L-thyroxine treatment on bone mineral density in young adults with congenital hypothyroidism. Eur J Endocrinol 2004;151:689-694.
132.
Oliviero U, Cittadini A, Bosso G, et al: Effects of long-term L-thyroxine treatment on endothelial function and arterial distensibility in young adults with congenital hypothyroidism. Eur J Endocrinol 2010;162:289-294.
133.
Grasberger H, Refetoff S: Genetic causes of congenital hypothyroidism due to dyshormonogenesis. Curr Opin Pediatr 2011;23:421-428.
134.
Devos H, Rodd C, Gagné N, Laframboise R, Van Vliet G: A search for the possible molecular mechanisms of thyroid dysgenesis: sex ratios and associated malformations. J Clin Endocrinol Metab 1999;84:2502-2506.
135.
Castanet M, Lyonnet S, Bonaïti-Pellié C, Polak M, Czernichow P, Léger J: Familial forms of thyroid dysgenesis among infants with congenital hypothyroidism. N Engl J Med 2000;343:441-442.
136.
Perry R, Heinrichs C, Bourdoux P, et al: Discordance of monozygotic twins for thyroid dysgenesis: implications for screening and for molecular pathophysiology. J Clin Endocrinol Metab 2002;87:4072-4077.
137.
Léger J, Marinovic D, Garel C, Bonaïti-Pellié C, Polak M, Czernichow P: Thyroid developmental anomalies in first degree relatives of children with congenital hypothyroidism. J Clin Endocrinol Metab 2002;87:575-580.
138.
Park SM, Chatterjee VK: Genetics of congenital hypothyroidism. J Med Genet 2005;42:379-389.
139.
Krude H, Schütz B, Biebermann H, et al: Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency. J Clin Invest 2002;109:475-480.
140.
Pohlenz J, Dumitrescu A, Zundel D, et al: Partial deficiency of thyroid transcription factor 1 produces predominantly neurological defects in humans and mice. J Clin Invest 2002;109:469-473.
141.
Castanet M, Mallya U, Agostini M, et al: Maternal isodisomy for chromosome 9 causing homozygosity for a novel FOXE1 mutation in syndromic congenital hypothyroidism. J Clin Endocrinol Metab 2010;95:4031-4036.
142.
Macchia PE, Lapi P, Krude H, et al: PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 1998;19:83-86.
143.
Bizhanova A, Kopp P: Genetics and phenomics of Pendred syndrome. Mol Cell Endocrinol 2010;322:83-90.
144.
Hishinuma A, Fukata S, Kakudo K, Murata Y, Ieiri T: High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. Thyroid 2005;15:1079-1084.
145.
Mantovani G: Clinical review: pseudohypoparathyroidism: diagnosis and treatment. J Clin Endocrinol Metab 2011;96:3020-3030.
146.
Ranzini AC, Ananth CV, Smulian JC, Kung M, Limbachia A, Vintzileos AM: Ultrasonography of the fetal thyroid: nomograms based on biparietal diameter and gestational age. J Ultrasound Med 2001;20:613-617.
147.
Ribault V, Castanet M, Bertrand AM, et al: Experience with intraamniotic thyroxine treatment in nonimmune fetal goitrous hypothyroidism in 12 cases. J Clin Endocrinol Metab 2009;94:3731-3739.
148.
Thorpe-Beeston JG, Nicolaides KH, McGregor AM: Fetal thyroid function. Thyroid 1992;2:207-217.
149.
Huel C, Guibourdenche J, Vuillard E, et al: Use of ultrasound to distinguish between fetal hyperthyroidism and hypothyroidism on discovery of a goiter. Ultrasound Obstet Gynecol 2009;33:412-420.
150.
Rodriguez MH: Polyhydramnios: does reducing the amniotic fluid volume decrease the incidence of prematurity? Clin Perinatol 1992;19:359-366.
151.
Polak M, Van Vliet G: Therapeutic approach of fetal thyroid disorders. Horm Res Paediatr 2010;74:1-5.
152.
Stoppa-Vaucher S, Francoeur D, Grignon A, et al: Non-immune goiter and hypothyroidism in a 19-week fetus: a plea for conservative treatment. J Pediatr 2010;156:1026-1029.
© 2014 S. Karger AG, Basel and The Endocrine Society
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
